Efficacy of anastrozole in a consecutive series of advanced breast cancer patients treated with multiple prior chemotherapies and endocrine agents: M.D. Anderson cancer center experience

Breast Journal

Volumn 5, Issue 3, 1999, Pages 176-181

  Knoche, A Jolynn ^a   Michaud, Laura Boehnke ^a,b   Buzdar, Aman U ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anastrozole; Endocrine therapy; Metastatic breast cancer

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ESTROGEN RECEPTOR; HORMONE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; ENDOCRINE SYSTEM; FEMALE; HORMONAL THERAPY; HUMAN; METASTASIS; POSTMENOPAUSE;

EID: 0033040325     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4741.1999.98055.x     Document Type: Article

References (8)

1. Buzdar AU, Jones SE, Vogel CL, et al. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Cancer 1997;79:730-39.
2. Jonat W, Howell A, Blomqvist C, et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal women with advanced breast cancer. Eur J Cancer 1996;32A:404-12.
3. Buzdar A, Jonat W, Howell A, Yin H, Lee D. Significant improved survival with Arimidex (anastrozole) versus megestrol acetate in postmenopausal advanced breast cancer: updated results of two randomized trials [abstract]. Proc Annu Meet Am Soc Clin Oncol 1997;16:A545.
4. Honig SF. Treatment of metastatic disease. In: Harris JR, Lippman ME, Morrow M, et al., eds. Diseases of the breast. Philadelphia: J.B. Lippincott, 1996:669-733.
5. Buzdar A, Jonat W, Howell A, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol 1996;14:2000-11.
6. Ingle JN, Johnson PA, Suman VJ, et al. A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma. Cancer 1997;80:218-24.
7. Perez JE, Machiavelli M, Leone BA, et al. Bone-only versus visceral-only metastatic pattern in breast cancer: analysis of 150 patients. Am J Clin Oncol 1990;13:294.
8. Sherry MM, Greco FA, Johnson DH, et al. Metastatic breast cancer confined to the skeletal system. Am J Med 1986; 81:381.